Novo Nordisk in August bought a plant in New Hampshire that Japan's Olympus Biologics was giving up. Now it is looking for people to help operate it.
The vaccinemaker Serum Institute of India, which jumped into the biosimilars race in July, is expanding its manufacturing network both in India and the Netherlands. The company says it will invest about $163 million for a new facility in its home country.
Swiss drugmaker Roche has plans for a big overhaul of its corporate headquarters. The drugmaker will spend about 3 billion Swiss francs ($3.2 billion) on a renovation that will add new labs and offices, and upgrade existing buildings on its Basel, Switzerland-based site.
Argos Therapeutics, which has a personalized immunotherapy drug to treat renal cell carcinoma in trials, has kicked off work on a $57 million manufacturing facility in North Carolina. The biotech will get nearly $10 million in public support for the project.
The U.S. government invested $440 million in three vaccine plants in the U.S. in 2012 with the proviso that if something like a pandemic occurred, it could call on them to produce drugs that it required. With Ebola spreading, those calls have now been made.
Puerto Rico, which has seen a number of plant closings recently, is facing another. Eli Lilly said it will close a facility in Guayama next year and put it up for sale.
U.S. drugmakers are not the only ones building plants in Ireland to take advantage of the lower taxes and incentives afforded there. Italian specialty drugmaker Cosmo says that is what it intends to do.
Abbott Laboratories, which has made a large bet on its global nutrition business, is in the final throw of a manufacturing triple play. The Chicago-area company this week opened a nutrition products plant in India after opening plants in the U.S. and China several months ago.
Construction of a $150 million plant that Novartis is building near St. Petersburg in Russia has been halted because of "technical reasons," just short of completion.
While GlaxoSmithKline's new drugs Anoro and Breo have yet to take flight like the company had hoped, the drugmaker has been expanding the North Carolina plant where it makes them and other respiratory drugs, expecting that they will.